title: Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry.
abstract: BACKGROUND
  Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines.
  
  
  OBJECTIVE
  The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals.
  
  
  METHODS
  The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction.
  
  
  CONCLUSIONS
  The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
authors.affiliation: Duke Clinical Research Institute, Durham, NC. Electronic address: navar006@mc.duke.edu.
authors.forename: Ann Marie
authors.initials: AM
authors.lastname: Navar
authors.affiliation: Duke Clinical Research Institute, Durham, NC.
authors.forename: Tracy Y
authors.initials: TY
authors.lastname: Wang
authors.affiliation: Washington University School of Medicine, St Louis, MO.
authors.forename: Anne C
authors.initials: AC
authors.lastname: Goldberg
authors.affiliation: University of Iowa, Iowa City, IA.
authors.forename: Jennifer G
authors.initials: JG
authors.lastname: Robinson
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Veronique L
authors.initials: VL
authors.lastname: Roger
authors.affiliation: Emory Clinical Cardiovascular Institute, Atlanta, GA.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Wilson
authors.affiliation: Michael E. Debakey Veterans Affaris Hospital and Baylor College of Medicine, Houston, TX.
authors.forename: Salim S
authors.initials: SS
authors.lastname: Virani
authors.affiliation: Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
authors.forename: Joesph
authors.initials: J
authors.lastname: Elassal
authors.affiliation: Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
authors.forename: L Veronica
authors.initials: LV
authors.lastname: Lee
authors.affiliation: Duke Clinical Research Institute, Durham, NC.
authors.forename: Laura E
authors.initials: LE
authors.lastname: Webb
authors.affiliation: Duke Clinical Research Institute, Durham, NC.
authors.forename: Eric
authors.initials: E
authors.lastname: Peterson
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011320:Primary Health Care / Q000379:methods*; D012042:Registries; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids